Acumen pharmaceuticals announces first patient dosed in altitude-ad, a phase 2 clinical trial of sabirnetug (acu193) in early alzheimer's disease

Charlottesville, va., may 08, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (aΒos) for the treatment of alzheimer's disease (ad), today announced that the first patient has been dosed with sabirnetug (acu193) in the altitude-ad phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early ad.
ABOS Ratings Summary
ABOS Quant Ranking